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ABSTRACT 
There are several reports available on neuroleptic malignant syndrome (NMS) associated with 
risperidone but when a more stringent criterion is applied there are only a few. Report on challenge 
and rechallenge with various atypical antipsychotic drugs in re-emergence of post NMS psychosis is 
scanty. Our aim of presenting this is to highlight the differential response of various atypical 
antipsychotic drugs in the treatment of post NMS psychosis. This paper reports a young male with 
mild mental retardation who developed NMS on a low dose of nspendone. Eariierhe was on haloperidol 
10 mg. which was stopped 10 days prior to initiation of risperidone therapy. Symptoms of NMS 
resolved within 36 hours with bromocnptine; but the patient relapsed to psychosis. Re-challenge with 
risperidone 1mg resulted in a dystonic reaction, with clozapine 12.5 mg he developed marked sedation, 
hypotension and urinary incontinence. Ultimately post NMS psychosis responded well to 
olanzapinelOmg and there was no recurrence of NMS. Olanzapine may be the better choice for the 
treatment of post NMS psychosis. 
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A review article by Hasan and Buckley in 
1988 identified 13 case of risperidone-induced 
NMS with variable diagnostic certainity. When the 
more stringent criteria of Caroff and Mann (1993) 
was applied, only five out of the thirteen cases 
were identified as being true NMS. Same article 
has drawn the tentative conclusion that NMS can 
occur with risperidone monotherapy but a 
proportion of these cases appear to have 
implicated risperidone inappropriately. A review on 
risperidone induced NMS observed that age and 
duration of exposure to risperidone did not seem 
to be of significance (Metenssian 1996) We found 
approximately 22 cases of risperidone-induced 
NMS after reviewing the literature in detail. Only 
single case report is available from India 
(Venkatasubramanian et al 2000). In most of these 
cases strategic plan for post NMS phase has been 
not discussed. This case report highlights NMS 
induced by risperidone, which was resolved within 
36 hours with bromocriptine and also highlights 
the differential response of various atypical 
neuroleptics. 
CASE REPORT 
Mr S, a 22- year- old male with mild mental 
retardation presented to us with symptoms of 
disinhibited behavior abusiveness running away 
from home, second person auditory hallucinations, 
delusions of persecution, delusions of reference 
and disturbed biological functioning of one and a 
half months duration. He was treated with 
haloperidol 15 mg/day and Trihexyphenidyl 4mg/ 
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day. He developed extrapyramidal symptoms 
(EPS) in the form of rigidity, bradykinesia and 
salivation, hence haloperidol was discontinued 
and his EPS was treated successfully with 
trihexyphenidyl 6mg /day. Within 10 days of 
stopping haloperidol and during recovery phase 
of EPS (mild) patient's psychosis worsened for 
which he was started on Risperidone 2mg. Six 
days later he was admitted to this hospital with 
symptoms of fever, unable to pass urine, not taking 
orally and stiffness of body of 2 days duration. 
On examination, he was found to be febrile with 
generalized rigidity and he also had retention of 
urine. His temperature varied from 100 F -102 F 
and pulse rate was 100-120 beats/minute. Blood 
pressure was labile and he exhibited symptoms 
of altered sensorium. Laboratory tests done on 
first day of admission revealed serum creatine 
phosphokinase (CPK) level of 370IU/L, albuminuria 
and a liver function tests showed deranged liver 
enzymes. A diagnosis of schizophreniform 
disorder with neuroleptic malignant syndrome was 
made. Risperidone was stopped immediately and 
patient was managed symptomatically with 
hydrotherapy and antipyretics. Bromocriptine 2.5 
mg in three divided doses was started. Serum 
CPK repeated on the next day was found to be 
further elevated to 1558 IU/L. There was no 
improvement in fever, rigidity and altered 
sensorium. Bromocriptine was increased to a dose 
of 12.5 mg/day. On the third day of admission, he 
became afebrile and was oriented to time, place 
and person. He showed marked improvement in 
rigidity, serum CPK decreased to 58 IU/L and 
autonomic instability also settled. These fall in 
serum CPK was continued and subsequent CPK 
was 36 IU/L and 30 IU/L. Bromocriptine was 
tapered and stopped over two weeks. Cranial CT 
done during the course of his stay in the hospital 
revealed nonspecific calcified granulomas in the 
right parieto-occipital region and in the left parietal 
region. Within two weeks after complete recovery 
from NMS patient started exhibiting psychotic 
behavior similar to the previous one Initially he 
was treated with 6 electro-convulsive therapies 
(ECT) for post NMS psychosis over a period of 
three weeks, but showed no significant 
improvement. In fact, he developed post-ECT 
memory disturbances. We have taken a separate 
informed consent from patient's father for 
challenging and re-chaJlenging with atypical 
antipsychotic drugs. With a single dose of 
clozapine 12.5 mg, he was sedated for 18 hours 
and had hypotension and urinary incontinence. 
Rechallange was done with risperidone 1mg but 
on the second day he developed dystonic reaction 
of the neck muscles. Ultimately he responded very 
well to gradual administration of olanzapine 15 
mg without developing any side effects. Serum 
CPK levels were done each time before increasing 
the dose of olanzapine and levels were within 
normal limits. At the time of discharge, serum 
CPK was 22 IU/L 
DISCUSSION 
Our patient fulfilled the major and minor 
criteria as given by Levenson (1985), Caroff and 
Mann (1993) and also as per DSM-IV (1994). 
Risperidone a benzisoxazole derivative has high 
serotonin 5HT2 receptor blockade and dose 
related D2 receptor blockade. It is believed that 
this ratio would cause low frequency of EPS at 
lower doses (Jeste et al.,1999) and thus prevent 
the occurrence of NMS. 
According to the most stringent criteria of 
Caroff and Mann (1993), a patient develops NMS 
within a week of oral use of neuroleptics and within 
2-4 weeks of depot neuroleptic use. Our patient 
developed NMS within 4 days of risperidone 
therapy thus suggesting a temporal correlation 
between NMS and risperidone use. Though the 
rapid fall in serum CPK correlated with clinical 
improvement earlier clinical presentation was not 
correlated well with CPK level, where CPK was 
only 370 despite of having full-blown NMS. This 
showed that CPK is a non-specific finding as seen 
in other study (O'Dwyer & Sheppard 1993). Our 
patient was mentally retarded and concomitant 
diagnoses of mental retardation was also found 
in other case reports with atypical and typical 
antipsychotic induced NMS (Hasan and Buckley 
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1998). Cranial CT scan finding could again have 
been a non-specific finding in our case. 
Literature regarding management of post 
NMS psychosis is scantly reported particularly 
on atypical neuroleptic induced NMS and 
subsequent psychosis probably because of rarity 
of condition. Studies have examined the issue of 
re-challenge with only typical neuroleptics in post 
NMS cases and demonstrated safety of re-
challenge (Rosenbush et al 1989 & Chopra & 
Raghuram 2001). Recent review showed that 19 
out of 45 reports of rechallenge with an atypical 
antipsychotic after NMS with a typical 
antipsychotic had recurrence of NMS. Another of 
45 rechallenges with a typical antipsychotic after 
NMS on a typical antipsychotic 17 had recurrences 
(Caroff et al 2000). This finding may be biased 
probably due to the lack of reporting of successful 
re-challenge with a new drug. Administration of 
high potency neuroleptic at a rapid loading 
appears to be crucial for recurrence of NMS on 
re-challenge (& Chopra & Raghuram 2001). 
Avoidance of neuroleptic drug for at least 2 weeks 
after complete recovery from NMS and gradual 
titration of low dose and low potency neuroleptic 
trial of newer anti psychotic such as clozapine 
may be useful to prevent recurrence of NMS 
(Bajjock et al 1997). In the review by Hassan and 
Buckley (1998) patients with typical antipsychotic 
induced NMS were given clozapine which they 
were able to tolerate without a recurrence of 
NMS.Three out of four patients with clozapine 
induced NMS were rechallenged with clozapine 
and one with risperidone without recurrence of 
NMS and subsequent problems. Both patients with 
risperidone induced NMS developed some 
symptoms of NMS when rechallenged. In contrast 
to these findings our case was dose-sensitive to 
clozapine and re-challenge with risperidone caused 
dystonia, which were the reasons to withdraw both 
neuroleptics. It is difficult to explain why this case 
showed good response to olanzapine A possible 
explanation may be the olanzapine's receptor 
binding profile seems to occupy an intermediate 
position between clozapine and risperidone. It has 
greater affinity for 5HT2a and D2 receptors than 
clozapine but lower affinities than risperidone 
(Moore et al., 1992) We have reviewed the recent 
case reports on olanzapine induced NMS In two 
cases, NMS probably has been promoted by the 
past history of conventional neuroleptic induced 
NMS (Gheorghiu et al., 1999 & Burkhard et al). 
Another case already had medical history of 
glaucoma, possible parkinsons disease and 
confusion. He was on olanzapine, nefazadone and 
received low dose of haloperidol 2 days prior to 
the onset of NMS (Hansen and Alderman 2000). 
One case of olanzapine induced NMS was already 
on benztropin mesylate and ranitidine (Stanfield 
& Privette 2000). This showed that some of the 
cases were not true cases of NMS Olanzapine 
is superior to risperidone in ameliorating both 
positive and negative symptoms in schizophrenia 
and other psychotic disorders (Tran et al., 1997). 
Clozapine causes agranulocytosis in about 1% 
of cases (Alvir et al., 1993) while non of the patients 
exhibited hematotoxicity among 2500 patients 
treated with olanzanzapine (Beasley et al 1997). 
In view of the available side effect profile of atypical 
antipsychotic drugs in post NMS phase, this case 
report showed that olanzapine may be the better 
choice for the treatment of post NMS psychosis. 
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